Press release
Transgene is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Its shares are admitted to trading on Euronext Paris.
It has successfully completed a fundraising of €105 million through the issuance of new shares to French and European investors specializing in the health sector via a private placement through an accelerated book building and to retail investors via an offer to the public in France and in certain other countries of the European Union through the PrimaryBid platform. Concurrently, it has carried out a capital increase reserved for TSGH (Institut Mérieux) of €39.3 million by way of set-off with the amounts advanced under a current account advance granted by TSGH to Transgene.
Transgene intends to use the net proceeds from the fundraising mainly to finance the acceleration of the myvac® program, including the conduct of the ongoing Phase 2 trial in head and neck cancer, the launch of a Phase 1 trial in a new indication, the optimization of manufacturing and initial work to prepare Transgene to launch a pivotal trial in head and neck cancer.
On this transaction, Transgene was advised by CMS Francis Lefebvre, with a team comprised of Bertrand Sénéchal, partner, Victor Delion, associate, and Natan Bisson-Kocanski, lawyer. David Rivera, counsel at CMS UK, advised on US securities law aspects.
The bank syndicate, advised by Goodwin, was comprised of Van Lanschot Kempen N.V. and Swiss Life Banque Privée.
